Literature DB >> 28100110

Mortality in Patients With Septic Shock by Multidrug Resistant Bacteria: Risk Factors and Impact of Sepsis Treatments.

Stefano Busani1, Giulia Serafini1, Elena Mantovani1, Claudia Venturelli2, Maddalena Giannella3, Pierluigi Viale3, Cristina Mussini4, Andrea Cossarizza5, Massimo Girardis1.   

Abstract

BACKGROUND: : Patients with septic shock by multidrug resistant (MDR) microorganism maybe considered a specific population of critical patients at very high risk of death in whom the effects of standard sepsis treatment has never been assessed. The objective of this retrospective analysis was to evaluate the risk factors for 30-day mortality and the impact of sepsis management in patients with septic shock caused by MDR bacteria.
METHODS: : Patients with septic shock by MDR bacteria admitted to the mixed intensive care unit (ICU) of Modena University Hospital during a 6-year period were studied. The clinical and microbiological characteristics and sepsis treatments provided were analyzed and compared between survivors (S) and nonsurvivors (NS) at 30 days after septic shock appearance.
RESULTS: : Ninety-four patients were studied. All therapeutic interventions applied to patients during their ICU stay did not show statistical significance between S and NS groups, except for administration of immunoglobulin M (IgM) preparation which were provided more frequently in S group ( P < .05). At the multivariate adjusted analysis, preexisting cancer (odds ratio [OR] = 2.965) and Acinetobacter baumannii infections (OR = 3.197) were independently correlated with an increased risk of 30-day mortality, whereas treatment with IgM preparation was protective (OR = 0.283).
CONCLUSIONS: : This retrospective study showed that in patients with septic shock caused by MDR bacteria, history of cancer and infection sustained by A baumannii increase the risk of mortality and that standard sepsis treatments do not seem to provide any protective effect. Adjunctive therapy with IgM preparation seems to be beneficial, but further appropriate studies are needed to confirm the results observed.

Entities:  

Keywords:  host immune response; multidrug resistant bacteria; sepsis bundle treatment; septic shock

Year:  2017        PMID: 28100110     DOI: 10.1177/0885066616688165

Source DB:  PubMed          Journal:  J Intensive Care Med        ISSN: 0885-0666            Impact factor:   3.510


  12 in total

Review 1.  Immune therapy in sepsis: Are we ready to try again?

Authors:  Roger Davies; Kieran O'Dea; Anthony Gordon
Journal:  J Intensive Care Soc       Date:  2018-04-04

2.  Epidemiology and Risk Factors Associated With Mortality in Consecutive Patients With Bacterial Bloodstream Infection: Impact of MDR and XDR Bacteria.

Authors:  Antonella Santoro; Erica Franceschini; Marianna Meschiari; Marianna Menozzi; Stefano Zona; Claudia Venturelli; Margherita Digaetano; Carlotta Rogati; Giovanni Guaraldi; Mical Paul; Inge C Gyssens; Cristina Mussini
Journal:  Open Forum Infect Dis       Date:  2020-09-30       Impact factor: 3.835

3.  Comparison of Septic Shock Due to Multidrug-Resistant Acinetobacter baumannii or Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Intensive Care Unit Patients.

Authors:  Alessandro Russo; Simone Giuliano; Giancarlo Ceccarelli; Francesco Alessandri; Alessandra Giordano; Grazia Brunetti; Mario Venditti
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

4.  The Influence of Host Stress on the Mechanism of Infection: Lost Microbiomes, Emergent Pathobiomes, and the Role of Interkingdom Signaling.

Authors:  John C Alverdy; James N Luo
Journal:  Front Microbiol       Date:  2017-03-02       Impact factor: 5.640

5.  Increased Plasma Levels of Mitochondrial DNA and Normal Inflammasome Gene Expression in Monocytes Characterize Patients With Septic Shock Due to Multidrug Resistant Bacteria.

Authors:  Stefano Busani; Sara De Biasi; Milena Nasi; Annamaria Paolini; Sophie Venturelli; Martina Tosi; Massimo Girardis; Andrea Cossarizza
Journal:  Front Immunol       Date:  2020-05-05       Impact factor: 7.561

6.  Determinants of Mortality in Patients with Nosocomial Acinetobacter baumannii Bacteremia in Southwest China: A Five-Year Case-Control Study.

Authors:  Shuangshuang Yang; Jide Sun; Xianan Wu; Liping Zhang
Journal:  Can J Infect Dis Med Microbiol       Date:  2018-06-03       Impact factor: 2.471

7.  In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii.

Authors:  Mario Juhas; Emma Widlake; Jeanette Teo; Douglas L Huseby; Jonathan M Tyrrell; Yury S Polikanov; Onur Ercan; Anna Petersson; Sha Cao; Ali F Aboklaish; Anna Rominski; David Crich; Erik C Böttger; Timothy R Walsh; Diarmaid Hughes; Sven N Hobbie
Journal:  J Antimicrob Chemother       Date:  2019-04-01       Impact factor: 5.790

Review 8.  Antibiotic-Resistant Septicemia in Pediatric Oncology Patients Associated with Post-Therapeutic Neutropenic Fever.

Authors:  Rosalino Vázquez-López; Omar Rivero Rojas; Andrea Ibarra Moreno; José Erik Urrutia Favila; Adan Peña Barreto; Guadalupe Lizeth Ortega Ortuño; Jorge Andrés Abello Vaamonde; Ivanka Alejandra Aguilar Velazco; José Marcos Félix Castro; Sandra Georgina Solano-Gálvez; Tomás Barrientos Fortes; Juan Antonio González-Barrios
Journal:  Antibiotics (Basel)       Date:  2019-07-30

9.  Risk factors for nosocomial rectal colonization with carbapenem-resistant Acinetobacter baumannii in hospital: a matched case-control study.

Authors:  Marianna Meschiari; Shaniko Kaleci; Gabriella Orlando; Silvia Selmi; Antonella Santoro; Erica Bacca; Marianna Menozzi; Erica Franceschini; Cinzia Puzzolante; Andrea Bedini; Mario Sarti; Claudia Venturelli; Elena Vecchi; Cristina Mussini
Journal:  Antimicrob Resist Infect Control       Date:  2021-04-08       Impact factor: 4.887

10.  Effect of N-Acetylcysteine Administration on 30-Day Mortality in Critically Ill Patients with Septic Shock Caused by Carbapenem-Resistant Klebsiella pneumoniae and Acinetobacter baumannii: A Retrospective Case-Control Study.

Authors:  Alessandra Oliva; Alessandro Bianchi; Alessandro Russo; Giancarlo Ceccarelli; Francesca Cancelli; Fulvio Aloj; Danilo Alunni Fegatelli; Claudio Maria Mastroianni; Mario Venditti
Journal:  Antibiotics (Basel)       Date:  2021-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.